Alec Bradbury
Family · Costa Mesa, CANPI 1902557226
Payments from drug & device makers
Across 145 payments — averaging $129.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$17K
- AbbVie$580
- Novo Nordisk$277
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$197
- Vanda Pharmaceuticals Inc.$163
- Braeburn Inc.$121
- plus $502 from 12 others
What the payments were for
- Speaking & faculty fees$13,37071%
- Travel & lodging$1,4057%
- Food & beverage$3,98821%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 75 | $16,969 |
| AbbVie | 24 | $580 |
| Novo Nordisk | 9 | $277 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $197 |
| Vanda Pharmaceuticals Inc. | 6 | $163 |
| Braeburn Inc. | 1 | $121 |
| Indivior Inc. | 5 | $110 |
| Otsuka America Pharmaceutical, Inc. | 5 | $107 |
| Lilly USA, LLC | 2 | $43 |
| Pfizer | 1 | $38 |
| Amgen | 2 | $36 |
| Neurocrine Biosciences, Inc. | 1 | $34 |
| Exact Sciences | 1 | $27 |
| GSK | 1 | $24 |
| Organon | 1 | $24 |
| Theratechnologies Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Cranial Technologies, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,809 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,836 |
| Levetiracetam | 24 | $717 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $698 |
| Gabapentin | 32 | $422 |
| Atorvastatin Calcium | 54 | $386 |
| Verapamil ErVerapamil Hcl | 11 | $262 |
| Levothyroxine Sodium | 20 | $260 |
| Lisinopril | 31 | $239 |
| Omeprazole | 20 | $202 |
| Tamsulosin Hcl | 20 | $142 |
| Metformin Hcl | 11 | $132 |
| Furosemide | 26 | $126 |
| Amlodipine Besylate | 12 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $24 | $7,83619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Costa Mesa
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.